This study is currently not recruiting participants.

Compassionate Use of DCVax-L Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Malignant Glioma

Investigating an Investigational Therapy for Glioblastoma, a Type of Brain Cancer

Not Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

To provide compassionate use access to DCVax-L for cancer patients with glioblastoma.

Detailed description of study

To provide compassionate use access to DCVax-L for cancer patients with glioblastoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Brain Cancer
  • Age: 100 years or below
  • Gender: All

This study investigates an investigational therapy for patients with glioblastoma, a type of brain cancer. Glioblastoma is a fast-growing cancer that occurs in the brain or spinal cord. The investigational therapy being studied aims to provide new treatment options for this condition.

Participants in this study will receive the investigational therapy. The study will monitor the effects and safety of this therapy in patients with glioblastoma.

  • Who can participate: Patients diagnosed with glioblastoma, typically aged 18 and older, may be eligible to participate.
  • Study details: Participants will receive the investigational therapy as part of the study. The study will include monitoring to assess the therapy's effects and safety.
Updated on 19 Feb 2024. Study ID: 1305011359

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team